HK1205788A1 - Elevated psma identifies lethal prostate cancers - Google Patents

Elevated psma identifies lethal prostate cancers Download PDF

Info

Publication number
HK1205788A1
HK1205788A1 HK15106199.9A HK15106199A HK1205788A1 HK 1205788 A1 HK1205788 A1 HK 1205788A1 HK 15106199 A HK15106199 A HK 15106199A HK 1205788 A1 HK1205788 A1 HK 1205788A1
Authority
HK
Hong Kong
Prior art keywords
adenocarcinomas
psma
lethal
identifies
tumors
Prior art date
Application number
HK15106199.9A
Other languages
English (en)
Chinese (zh)
Inventor
Neil H. Bander
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of HK1205788A1 publication Critical patent/HK1205788A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Reproductive Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
HK15106199.9A 2012-02-24 2013-02-22 Elevated psma identifies lethal prostate cancers HK1205788A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261602900P 2012-02-24 2012-02-24
US61/602,900 2012-02-24
PCT/US2013/000045 WO2013126147A2 (en) 2012-02-24 2013-02-22 Elevated psma identifies lethal prostate cancers

Publications (1)

Publication Number Publication Date
HK1205788A1 true HK1205788A1 (en) 2015-12-24

Family

ID=49003541

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106199.9A HK1205788A1 (en) 2012-02-24 2013-02-22 Elevated psma identifies lethal prostate cancers

Country Status (6)

Country Link
US (2) US20130225541A1 (enExample)
EP (2) EP3064945A1 (enExample)
JP (2) JP6501524B2 (enExample)
CA (1) CA2865282A1 (enExample)
HK (1) HK1205788A1 (enExample)
WO (1) WO2013126147A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1202256A1 (en) * 2012-02-28 2015-09-25 Cornell University Psma as a biomarker for androgen activity in prostate cancer
US10340046B2 (en) 2016-10-27 2019-07-02 Progenics Pharmaceuticals, Inc. Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications
CA3050085A1 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
CA3056261A1 (en) 2017-04-07 2018-10-11 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
US12602772B2 (en) 2018-01-08 2026-04-14 Progenics Pharmaceuticals, Inc. Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination
CN113272859B (zh) 2019-01-07 2025-04-04 西尼诊断公司 用于平台中立性全身图像分段的系统及方法
TWI872062B (zh) 2019-04-24 2025-02-11 美商普吉尼製藥公司 用於偵測轉移之骨掃描影像之自動及互動式分析系統、裝置及方法
US12417533B2 (en) 2019-09-27 2025-09-16 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
US11900597B2 (en) 2019-09-27 2024-02-13 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
IL320607A (en) 2020-03-26 2025-07-01 Ramirez Fort Marigdalia Kaleth Ultraviolet radiation treatments
US11721428B2 (en) 2020-07-06 2023-08-08 Exini Diagnostics Ab Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions
AU2022361659A1 (en) 2021-10-08 2024-03-21 Exini Diagnostics Ab Systems and methods for automated identification and classification of lesions in local lymph and distant metastases
CN119791845B (zh) * 2025-01-03 2026-05-08 北京大学第一医院(北京大学第一临床医学院) 一种降低前列腺根治性切除术后切缘阳性的治疗设备

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098885A1 (en) * 2001-02-07 2002-12-12 Beth Israel Deaconess Medical Center Modified psma ligands and uses related thereto
JP4619651B2 (ja) * 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
ATE408712T1 (de) * 2003-01-10 2008-10-15 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
WO2005021709A2 (en) * 2003-05-29 2005-03-10 Diadexus, Inc. Cln101 antibodies
RU2450832C2 (ru) * 2006-10-25 2012-05-20 Конинклейке Филипс Электроникс Н.В. Контрастные вещества для детекции рака предстательной железы
WO2009046294A2 (en) * 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
EP2281004A4 (en) * 2008-04-14 2012-02-15 Proscan Rx Pharma Inc PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
WO2010065940A1 (en) * 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
EP3495000A1 (en) * 2009-02-17 2019-06-12 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
US8772226B2 (en) * 2009-03-17 2014-07-08 The Johns Hopkins University Methods and compositions for the detection of cancer

Also Published As

Publication number Publication date
JP2015513083A (ja) 2015-04-30
EP3064945A1 (en) 2016-09-07
EP2817629A2 (en) 2014-12-31
WO2013126147A3 (en) 2014-12-24
JP6501524B2 (ja) 2019-04-17
US20130225541A1 (en) 2013-08-29
WO2013126147A2 (en) 2013-08-29
JP2019144254A (ja) 2019-08-29
US20180088120A1 (en) 2018-03-29
EP2817629A4 (en) 2016-01-13
CA2865282A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
WO2013126147A3 (en) Elevated psma identifies lethal prostate cancers
HK1257310A1 (zh) 抗-cd47抗体及使用方法
WO2019028285A3 (en) Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
HK1219763A1 (zh) 用於癌症预後的组合物和方法
WO2011139721A8 (en) Cancer biomarkers and methods of use thereof
MX2018002237A (es) Nuevos biomarcadores y metodos para tratar el cancer.
WO2014144121A3 (en) Classification and actionability indices for lung cancer
HK1255533A1 (zh) 用於检测大肠癌及进阶性腺瘤的蛋白质生物标志物面板
WO2016172710A3 (en) Methods and reagents for determination and treatment of organotropic metastasis
WO2014153056A3 (en) Cancer treatment using antibodies that bing cell surface grp78
EP3290082A3 (en) Methods and devices for stimulating an immune response using nanosecond pulsed electric fields
HK1217375A1 (zh) 结果跟踪与分析的系统和方法
EA201690599A1 (ru) Конъюгированные антитела против ly75 для лечения рака
EP4524569A3 (en) Methods, compositions and devices for treating cancer with illudofulvenes
MY180834A (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
MX2017006609A (es) Aditivo de nanocristales de celulosa o nanofibrillas de celulosa modificadas de forma quimica.
MX2019013953A (es) Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia.
HK1220253A1 (zh) 诊断前列腺癌症的方法
WO2018046770A3 (en) Marker and target as a diagnostic variable and target for therapy of metastatic cancer
WO2014205132A3 (en) Methods and compositions to treat cancer
EP3693742A3 (en) Methods of detecting prostate cancer
ES2672989T3 (es) FALZ para su uso como diana para terapias para tratar el cáncer
WO2015181555A8 (en) Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent
WO2014143794A3 (en) Diagnostic and prognostic marker for prostate cancer
WO2018148180A3 (en) Materials and methods for identifying and treating cancer patients